U.S. pharma large copyright scrapped two experimental weight loss pills past year—a when-everyday capsule, lotiglipron, due to elevated liver enzymes as well as a two times-day-to-day tablet, danuglipron, as a consequence of robust Unintended effects—but CEO Albert Bourla has said th